Opendata, web and dolomites

SYNTRAIN SIGNED

Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYNTRAIN project word cloud

Explore the words cloud of the SYNTRAIN project. It provides you a very rough idea of what is the project "SYNTRAIN" about.

prospects    complementary    capacities    mechanistic    brca2    world    compound    inactivated    academia    combining    death    syntrain    breast    synthetic    constitute    basic    sme    cell    train    advantage    cancer    lethal    skills    young    clinically    interactions    members    cells    mass    acquired    generation    health    excellent    gap    industry    dna    genome    scientific    screening    redundant    kill    innovate    training    preparing    inherent    investigations    instability    academic    pursue    ovarian    creative    facetted    repair    etn    bridging    discovery    gene    sparing    entrepreneurial    normal    treatments    pioneered    consisting    mutation    enhances    maintenance    combinations    individual    techniques    mutations    pharma    stress    genetic    structured    serious    exceeds    capacity    genes    consists    inactivating    expertise    frame    therapeutic    takes    educate    career    drug    lethality    critical    innovative    beneficiary   

Project "SYNTRAIN" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.syntrain.ku.dk
 Total cost 3˙990˙269 €
 EC max contribution 3˙990˙269 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2016
 Funding Scheme MSCA-ITN-ETN
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 580˙163.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 546˙575.00
3    KANCERA AB SE (SOLNA) participant 527˙318.00
4    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 527˙318.00
5    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) participant 510˙748.00
6    KRAEFTENS BEKAEMPELSE DK (KOEBENHAVN) participant 290˙081.00
7    UNIVERSITE DE GENEVE CH (GENEVE) participant 265˙226.00
8    IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE IT (MILANO) participant 258˙061.00
9    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 242˙386.00
10    PANEPISTIMIO PATRON EL (RIO PATRAS) participant 242˙386.00
11    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) partner 0.00
12    MISVIK BIOLOGY OY FI (TURKU) partner 0.00
13    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) partner 0.00

Map

 Project objective

Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pursue a multi-facetted synthetic lethal approach, which takes advantage of the inherent genetic instability of cancer cells. Most mutations acquired by cancer cells do not cause lethality, but the very same mutations may cause cell death when a second gene in a redundant pathway is inactivated. Thus, targeting a gene that is synthetic lethal together with a cancer-specific mutation will kill only cancer cells while sparing normal cells. Synthetic lethal approaches have been clinically pioneered by members of our consortium, by combining cancer-promoting mutations (e.g. in BRCA2) with inactivating combinations of DNA repair genes. We will use this approach as the scientific frame for our ETN (SYNTRAIN) consisting of 9 academic and 1 SME beneficiary as well as 3 partners. We aim to identify synthetic lethal interactions and exploit them to innovate future breast and ovarian cancer treatments through compound screening and development. SYNTRAIN consists of World leading researchers with complementary knowledge in genome maintenance and stress response pathways, and a critical mass of expertise for providing an excellent training in screening methodologies, mechanistic investigations, and drug discovery. We will offer a structured training program that exceeds the capacities of each individual member. We will educate a future generation of cancer researchers with a high innovative capacity and skills that enhances their career prospects in both academia and industry. Our aims are to train young researchers: i) in techniques preparing for a career in cancer research, ii) in complementary skills relevant for work in academia and the pharma industry and iii) to become creative and entrepreneurial, capable of bridging the gap between basic and applied research.

 Deliverables

List of deliverables.
SYNTRAIN website Websites, patent fillings, videos etc. 2019-07-18 19:16:30

Take a look to the deliverables list in detail:  detailed list of SYNTRAIN deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Timo Reisländer, Emilia Puig Lombardi, Florian J. Groelly, Ana Miar, Manuela Porru, Serena Di Vito, Benjamin Wright, Helen Lockstone, Annamaria Biroccio, Adrian Harris, Arturo Londoño-Vallejo, Madalena Tarsounas
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-11048-5
Nature Communications 10/1 2020-03-05
2018 Panagiotis Galanos, George Pappas, Alexander Polyzos, Athanassios Kotsinas, Ioanna Svolaki, Nickolaos N. Giakoumakis, Christina Glytsou, Ioannis S. Pateras, Umakanta Swain, Vassilis L. Souliotis, Alexandros G. Georgakilas, Nicholas Geacintov, Luca Scorrano, Claudia Lukas, Jiri Lukas, Zvi Livneh, Zoi Lygerou, Dipanjan Chowdhury, Claus Storgaard Sørensen, Jiri Bartek, Vassilis G. Gorgoulis
Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability
published pages: , ISSN: 1474-760X, DOI: 10.1186/s13059-018-1401-9
Genome Biology 19/1 2019-07-18
2018 Eirini-Stavroula Komseli, Ioannis S. Pateras, Thorbjørn Krejsgaard, Konrad Stawiski, Sophia V. Rizou, Alexander Polyzos, Fani-Marlen Roumelioti, Maria Chiourea, Ioanna Mourkioti, Eleni Paparouna, Christos P. Zampetidis, Sentiljana Gumeni, Ioannis P. Trougakos, Dafni-Eleftheria Pefani, Eric O’Neill, Sarantis Gagos, Aristides G. Eliopoulos, Wojciech Fendler, Dipanjan Chowdhury, Jiri Bartek, Vassilis G. Gorgoulis
A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence
published pages: 37-58, ISSN: 1471-2164, DOI: 10.1186/s12864-017-4375-1
BMC Genomics 19/1 2019-07-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYNTRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

FutureArctic (2019)

A glimpse into the Arctic future: equipping a unique natural experiment for next-generation ecosystem research

Read More  

LIVE-I (2020)

Lightening and Innovating transmission for improving Vehicle: Environmental Impacts

Read More